Evidence map›Paper›PMID 40356390›Full record

ArticleRecent advances in anti-infective drug discovery2025

Noha Sabry Mokhtar, Sabha Mahmoud El-Sabagh, Aly Fahmy Mohamed, Hanaa Mohamed Salama, Mohammed Yosri Afifi, Basma Hamdy Amin

Abstract read
PubMed Publisher
In one paragraph

Article in Recent advances in anti-infective drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Noha Sabry MokhtarDepartment of Botany and Microbiology, Faculty of Science, Menoufia University, Menoufia, 32511, Egypt.
Sabha Mahmoud El-SabaghDepartment of Botany and Microbiology, Faculty of Science, Menoufia University, Menoufia, 32511, Egypt.
Aly Fahmy MohamedInternational Center for Training and Advanced Researches (ICTAR-Egypt), Cairo, Egypt.
Hanaa Mohamed SalamaDepartment of Chemistry, Faculty of Science, Port Said University, Port Said 42521, Egypt.
Mohammed Yosri AfifiThe Regional Center for Mycology and Biotechnology, Al-Azhar University, 11787, Nasr City, Cairo, Egypt.
Basma Hamdy AminThe Regional Center for Mycology and Biotechnology, Al-Azhar University, 11787, Nasr City, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundViral infections pose a great burden for humankind and many viruses have no effective treatments. Hepatitis A Virus (HAV) and Coxsackie-B4 (Cox- B4) are common viruses having many drawbacks. Using plant extracts as antiviral agents is a globally applied approach due to its efficacy and minimal adverse effects.

objectiveThis study aimed to test the antiviral action of the green coffee extract against HAV and Cox-B4 viruses, assess the possible mechanisms regulating this role, and apply molecular docking to evaluate the connection between bioactive compounds in the green coffee extract and viral proteins and receptors.

methodsThe antiviral effect of four plant extracts, including green tea, green coffee, pomegranate peel, and orange peel on HAV and Cox-B4 viruses has been screened in this study. The most promising results have been obtained using an inverted microscope and electron microscopy. Gas Chromatography-Mass Spectrometry (GC-MS) has been used to detect various compounds in the green coffee extract. Gene expression of MxA has been examined in different groups of treatments. Oxidative enzymes, including Glutathione (GSH), Superoxide Dismutase (SOD), and Malondialdehyde (MDA) were tested in infected Vero cells (African green monkey kidney cells) and upon using green coffee. In silico studies were performed using molecular docking software.

resultsGreen coffee has been found to have an antiviral impact on HAV and Cox-B4 with IC

conclusionGreen coffee methanolic extract has been found to have an efficient antiviral impact on HAV and Cox-B4 viruses, as validated by

Indexed as

Antiviral AgentsCitrus sinensisCoffeaCoffeeHepatitis A virusPlant ExtractsPomegranateTeaAnimalsCamellia sinensisChlorocebus aethiopsComputer SimulationHumansMolecular Docking SimulationVero CellsAntiviral AgentsCoffeePlant ExtractsTeaAntiviralCox-B4docking.green coffeehepatitis A virusTEM

Identifiers

PMID40356390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.